Aussie Investors Mull Injunction To Block Ventracor Sale To U.S. Firm
This article was originally published in PharmAsia News
A group of investors is considering taking Australia's Ventracor to court to block its proposed sale to U.S.-based Orqis Medical. Orqis is believed to be the only bidder for Ventracor, but dissident shareholders say the price offered is much too low. Other shareholders are trying to get the company to recapitalize and raise enough funds to tide Ventracor over until its VentrAssist implantable heart pump gains U.S. approval, expected later this year. (Click here for more
You may also be interested in...
This month’s column covers deals announced between 1-23 April 2020.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR - How To Survive Changing And Confusing Times
May 26 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.
Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares.